Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Kidney cancer

PBRM1 loss promotes tumour response to immunotherapy

Nature Reviews Clinical Oncology volume 15, pages 134–135 (2018)Cite this article

Subjects

The selective response of tumours to immune checkpoint blockade (ICB) therapy can be due to tumour-intrinsic features, such as mutational load in melanoma and non-small-cell lung cancer. Clear cell renal cell carcinoma (ccRCC) has a similar ICB response rate to these cancers despite having a much lower mutational load. Now, Miao et al. identify genomic alterations that influence the response of patients with metastatic ccRCC to ICB therapy with the anti-PD-1 antibody nivolumab.

“We performed whole-exome and transcriptome profiling of paired tumour samples and nonmalignant tissues from 35 patients with ccRCC receiving ICB, followed by computational analysis to discern genomic features that were enriched in patients that responded to ICB therapy,” explains Eliezer Van Allen. The findings from the discovery cohort were confirmed by testing a validation cohort of 63 patients with metastatic ccRCC who were receiving ICB therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Miao, D. et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science https://doi.org/10.1126/science.aan5951 (2018)

    Article  CAS  Google Scholar 

Download references

Authors
  1. Grant Otto
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Otto, G. PBRM1 loss promotes tumour response to immunotherapy. Nat Rev Clin Oncol 15, 134–135 (2018). https://doi.org/10.1038/nrclinonc.2018.12

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2018.12

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer